J
J Xing
Researcher at Bristol-Myers Squibb
Publications - 5
Citations - 803
J Xing is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Belatacept & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 718 citations.
Papers
More filters
Journal ArticleDOI
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)
Antoine Durrbach,José Osmar Medina Pestana,Thomas C. Pearson,Flavio Vincenti,Valter Duro Garcia,Josep M. Campistol,M. del Carmen Rial,Sander Florman,A. Block,G. Di Russo,J Xing,P. Garg,Josep M. Grinyó +12 more
TL;DR: ECD kidney transplant recipients treated with belatacept‐based immunosuppression achieved similar patient/graft survival, better renal function, had an increased incidence of PTLD, and exhibited improvement in the cardiovascular/metabolic risk profile versus cyclosporine‐treated patients.
Journal ArticleDOI
Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.
Flavio Vincenti,Christian P. Larsen,Josefina Alberú,Barbara A. Bresnahan,Valter Duro Garcia,J. Kothari,Peter Lang,E. Mancilla Urrea,Pablo U. Massari,G. A. Mondragón‐Ramirez,Rafael Reyes-Acevedo,Kim Rice,Lionel Rostaing,Steven M. Steinberg,J Xing,M. Agarwal,M. B. Harler,Bernard Charpentier +17 more
TL;DR: Belatacept‐treated patients maintained a high rate of patient and graft survival that was comparable to cyclosporine‐ treated patients, despite an early increased occurrence of acute rejection and PTLD.
Journal ArticleDOI
Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
L. De Prado Gomez,Asif Khan,Anju T. Peters,Claus Bachert,Martin Wagenmann,Enrico Heffler,Claire Hopkins,Peter Hellings,Mei Zhang,J Xing,Paul Rowe,Juby A. Jacob-Nara +11 more
TL;DR: Evaluating trEatment RESponses of dupilumab vs omalizumab in Type 2 patients is the first head-to-head trial assessing the comparative efficacy and safety of 2 biologics in patients with severe CRSwNP and comorbid asthma.
Renal function in patients treated with belatacept-or cyclosporine-based regimens at year 3 in the benefit and benefit-ext studies
A Durrbach,Franco Citterio,L Mulloy,E David Neto,Graeme R. Russ,Stefan Vitko,R Zhang,J Xing,M. B. Harler,J. Grinyo +9 more
Journal ArticleDOI
Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design
L. De Prado Gomez,Ian D. Pavord,W. Busse,Christopher E. Brightling,Michael E. Wechsler,Klaus F. Rabe,Mei Zhang,J Xing,Juby A. Jacob-Nara,Paul Rowe +9 more
TL;DR: The ATLAS trial as mentioned in this paper is designed to evaluate the role of dupilumab in preventing/slowing lung function decline over a period of 3 years versus standard-of-care therapy.